Heart failure is one of the most important cardiovascular public health burdens in contemporary medicine. Join Ileana L Piņa, MD in a discussion of the National Heart Failure Training Programs (N-HeFT) strategies for the identification of treatment gaps and improving care in heart failure.
Congestion, volume overload, dyspnea, decompensation all leading to hospitalization. Just what starts this cascade and how does a clinician stop the cycle. Is it as simple as a prescribing a diuretic? Don't bet on it.
Drs Eckel, Bakris, Brown, Haffner and Leahy evaluate the link between obesity and inflammation and its impact on cardiometabolic risk. Describe the interrelationship between diabetes, hypertension, and atherosclerosis as cardiometabolic risk factors. Identify lifestyle modifications and pharmacologic treatments for cardiometabolic risk reduction. They also discuss potential role of new therapies for the prevention and management of obesity.
ADHF, a double edged sword-a failing heart and failing kidneys. Relying on diuretics alone may not be the optimal approach. New therapies offer promise, but are they safe? Join Drs Greenberg, Piņa, and Carson.
Congestion is often what gets heart failure patients in trouble and, in the hospital. Currently available modalities aimed at volume overload are not perfect; safety concerns over adverse effects often limit use. A new class of agents offers promise.
